Core Viewpoint - QScreen AI Inc is launching a non-brokered private placement to raise up to C$500,000 by issuing up to 10,000,000 units at a price of C$0.05 per unit, aimed at advancing health screening and employee wellness initiatives [1][3]. Group 1: Private Placement Details - The offering consists of units, each comprising one common share and one half of a common share purchase warrant, with warrants allowing the purchase of one half common share at C$0.15 for 36 months [2]. - If the volume weighted average price of the common shares reaches or exceeds C$0.30 for 10 consecutive trading days, the company may accelerate the expiry date of the warrants [2]. Group 2: Use of Proceeds - Proceeds from the financing will support structured pilot discussions and operational integration planning with select organizations, building on recent engagements in Mexico [3]. - Funds will also be allocated to working capital needs associated with scaling commercialization efforts across healthcare, industrial, and technology sectors [3]. Group 3: Market Interest - The company has received preliminary indications of interest from select investors for participation in the private placement, indicating strong market interest in its commercialization initiatives [4]. Group 4: Company Overview - QScreen AI Inc is an emerging provider of rapid health screening and remote patient care solutions, utilizing proprietary AI technology to analyze physiological data and predict various health issues [5]. - The company's Smarthealth AI stations analyze 19 physiological vital parameters and can assess impairment by drugs or alcohol, fatigue, and mental illnesses [5].

Core Viewpoint - QScreen AI Inc. has entered into an independent contractor agreement with Global Frontier Advisors L.P. to enhance its business development and commercialization efforts in various sectors, particularly focusing on health and safety technology [1][2]. Company Overview - QScreen AI Inc. is a provider of rapid health screening and remote patient care solutions, utilizing proprietary AI technology to analyze physiological data and predict health issues [4]. - The company's Smarthealth AI stations can assess 19 physiological vital parameters and detect impairments due to drugs, alcohol, fatigue, or mental illnesses [4]. Agreement Details - The agreement with GFA, effective January 30, 2026, includes equity-based and performance-based compensation, pending regulatory approvals [1]. - GFA will support QScreen AI in business development across correctional facilities, industrial settings, national security, and large public events [2]. Leadership and Expertise - The initiative will be led by Lieutenant General Michael S. Groen (Ret.), who has significant experience in the U.S. Department of Defense's Joint Artificial Intelligence Center [2]. - GFA specializes in strategic advisory services that connect national security, economic resilience, and market development, focusing on critical sectors like defense technologies and renewable energy [3].

Core Viewpoint - QScreen AI Inc. has officially changed its name from Predictmedix AI Inc. to better reflect its evolution into a broader screening and decision-intelligence platform, enhancing its market positioning and technology alignment [1][5][7]. Company Overview - QScreen AI Inc. is a provider of rapid health screening and remote patient care solutions globally, utilizing AI-powered Smarthealth AI stations to analyze physiological data and predict various health issues [8]. Name Change Details - The company's common shares will begin trading under the new symbol (CSE: QAI) on the Canadian Securities Exchange starting January 27, 2026, with no changes to share capital, business operations, or management [2][3][4]. Technological Evolution - The transition to QScreen AI Inc. signifies the company's advancement beyond traditional AI architectures, incorporating quantum-inspired and advanced computational techniques to enhance data processing and analysis [6][7]. Strategic Focus - The company aims to commercialize advanced, quantum-enhanced AI capabilities across healthcare, safety, and other high-value markets, with a focus on scaling and market penetration [7].

Core Insights - Predictmedix AI Inc. has been selected for the Official Canada Trade Mission to Mexico, highlighting its status as a leader in AI-enabled health and safety technology [1][4][11] Group 1: Trade Mission Details - The trade mission is scheduled for February 15–20, 2026, focusing on key cities such as Mexico City, Guadalajara, and Monterrey [1] - This elite delegation includes only the most export-ready Canadian innovators, aligning with Canada's strategic priorities for global commercial alliances [2] - The mission is led by the Honourable Dominic LeBlanc, Minister responsible for Canada-U.S. Trade, and aims to provide access to Mexican business leaders and government decision-makers [3] Group 2: Strategic Importance - Participation in the trade mission validates Predictmedix's commercial maturity and international market appeal [4][11] - The mission supports Canada's national agenda for export diversification and innovation leadership, coinciding with growing economic momentum with Mexico [6] - Mexico's market, with over 130 million people, offers tariff-free access under CUSMA, making it an ideal location for technology deployment [5] Group 3: Technological Advancements - Predictmedix is emphasizing its integration of quantum-inspired algorithms into its AI framework, enhancing data processing speeds and diagnostic precision [7][9] - The company is onboarding industry veterans to lead its regional distribution network, leveraging their relationships in Mexico's healthcare and industrial sectors [10] Group 4: Commercial Objectives - The mission aims to expand Predictmedix's international sales pipeline and secure high-impact distribution partners [8] - The company is positioned to capitalize on high-growth sectors such as advanced manufacturing, ICT and AI, cleantech, and clean energy [6]

Core Viewpoint - Predictmedix AI Inc. has successfully closed the final tranche of its non-brokered private placement, raising a total of $612,650 across all tranches, indicating strong investor interest and strategic alignment with long-term goals [2][3][5]. Group 1: Financial Details - In the final tranche, the company issued 3,050,000 units at a price of $0.05 per unit, resulting in gross proceeds of $152,500 [3][4]. - The total capital raised from all tranches of the offering amounts to $612,650 [3]. Group 2: Warrant Information - Each unit consists of one common share and one half of a common share purchase warrant, with each warrant allowing the purchase of one half common share at a price of C$0.15 for 36 months [4]. - If the volume weighted average price of the common shares reaches or exceeds $0.30 for 10 consecutive trading days, the company may accelerate the expiry date of the warrants [4]. Group 3: Strategic Approach - The company emphasized a disciplined, value-focused approach to the financing, prioritizing strategic contributions from investors over merely maximizing capital [5]. - The completion of this financing is expected to provide clarity and momentum for advancing initiatives in key markets [5]. Group 4: Company Overview - Predictmedix AI Inc. is an emerging provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict health issues [6]. - The company's Smarthealth AI stations can assess 19 physiological vital parameters and detect impairments due to drugs, alcohol, fatigue, or mental illnesses [6].